Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Loses Bid For Avodart Prostate Cancer Prevention Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.

You may also be interested in...



Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim

GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.

Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim

GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

The problems that GlaxoSmithKline and Merck had in trying to convince FDA's Oncologic Drugs Advisory Committee to add labeling on prostate cancer risk reduction to Avodart (dutasteride) and Proscar (finasteride) may have been avoided had the firms selected a stronger mortality endpoint for their trials.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel